PDMR Dealing
08/12/2025 15:15
RNS Number : 7024K Oxford Biomedica PLC 08 December 2025 PDMR Dealing Oxford, UK - 08 December 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Lisa Doman, Chief People Officer and Kyriacos Mitrophanous, Chief Innovation Officer have exercised their respective 3,057 SAYE 2022 options at an exercise price of £2.944 on 08 December 2025 and disposed of their respective 3,057 shares at an average price of £6.23026 per share on 08 December 2025. The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.
| 1. | Details of thePerson Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Lisa Doman | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Person Discharging Managerial Responsibility | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 2025-12-08 | ||||
| b) | Description of the financial instrument | SAYE Options over Ordinary Shares of 50 pence each | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of SAYE 2022 Options at £2.944 | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,057 £2.944 £8999.81 | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Lisa Doman | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Person Discharging Managerial Responsibility | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 2025-12-08 | ||||
| b) | Description of the financial instrument | Ordinary Shares of 50 pence each | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of transaction | Sale of shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,057 £6.23026 £19,045.90 | ||||
| 1. | Details of thePerson Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Kyriacos Mitrophanous | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Person Discharging Managerial Responsibility | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 2025-12-08 | ||||
| b) | Description of the financial instrument | SAYE Options over Ordinary Shares of 50 pence each | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of SAYE 2022 Options at £2.944 exercise price | ||||
| e) | Place of the transaction | Outside of the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,057 £2.944 £8999.81 | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Kyriacos Mitrophanous | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Person Discharging Managerial Responsibility | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 2025-12-08 | ||||
| b) | Description of the financial instrument | Ordinary Shares of 50 pence each | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of transaction | Sale of shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,057 £6.23026 £19,045.90 | ||||